eligibility_summary
Advanced/recurrent/metastatic NSCLC. Part 1: post-SOC, any prior lines. Part 2: progressed ≥1 line, cohorts by EGFR status and cMET IHC (A–D,F EGFR−, E/E2 EGFR+). Therapy caps: no-actionable ≤2 after platinum+ICI, actionable ≤3 incl targeted±ICI, METex14 ≥1 MET TKI, ≤2. Require measurable lesion and ECOG 0–1. Key excludes: recent RT/surgery, uncontrolled CNS mets, ILD/pneumonitis, serious infection, >G1 neuropathy, liver/corneal/vision disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05652868 tests MYTX-011, an antibody–drug conjugate (ADC) given IV every 21 days. Drug/intervention: MYTX-011 pairs a pH-dependent anti-cMET monoclonal antibody with the antimicrotubule payload monomethyl auristatin E (MMAE). Mechanism: the antibody binds the c-MET (HGFR) receptor on tumor cells, is internalized, and in acidic intracellular compartments releases MMAE, disrupting microtubules to induce G2/M arrest and apoptosis, pH-dependent binding is designed to enhance tumor-selective payload delivery. Cells/pathways targeted: cMET-expressing NSCLC, including tumors with cMET overexpression, MET amplification, or MET exon 14 skipping, cohorts also include EGFR-mutant NSCLC with elevated cMET. Targets the HGF/MET signaling axis and the microtubule network.